Lineage Cell Therapeutics Inc [AMEX: LCTX] loss -3.02% on the last trading session, reaching $1720000.0 price per share at the time.
Lineage Cell Therapeutics Inc represents 228.36 million in outstanding shares, while the company has a total market value of $213.56 million with the latest information. LCTX stock price has been found in the range of $0.9117 to $1.09.
If compared to the average trading volume of 1.72M shares, LCTX reached a trading volume of 23641753 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Lineage Cell Therapeutics Inc [LCTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LCTX shares is $3.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LCTX stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Craig Hallum have made an estimate for Lineage Cell Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 20, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on November 02, 2022, representing the official price target for Lineage Cell Therapeutics Inc stock. Previously, the target price had yet another raise to $4, while B. Riley Securities analysts kept a Buy rating on LCTX stock.
The Price to Book ratio for the last quarter was 2.70, with the Price to Cash per share for the same quarter was set at 0.21.
Trading performance analysis for LCTX stock
Lineage Cell Therapeutics Inc [LCTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.56. With this latest performance, LCTX shares gained by 43.37% in over the last four-week period, additionally plugging by 70.50% over the last 6 months – not to mention a rise of 86.11% in the past year of trading.
Lineage Cell Therapeutics Inc [LCTX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Lineage Cell Therapeutics Inc [LCTX] shares currently have an operating margin of -223.10% and a Gross Margin at 90.90%. Lineage Cell Therapeutics Inc’s Net Margin is presently recorded at -169.57%.
Return on Equity for this stock declined to -14.72%, with Return on Assets sitting at -14.72%.
Lineage Cell Therapeutics Inc [LCTX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LCTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lineage Cell Therapeutics Inc go to 9.01%.
An analysis of Institutional ownership at Lineage Cell Therapeutics Inc [LCTX]
There are presently around $47.94%, or 48.14% of LCTX stock, in the hands of institutional investors. The top three institutional holders of LCTX stocks are: BROADWOOD CAPITAL INC with ownership of 41.67 million shares, which is approximately 22.0675%. BLACKROCK INC., holding 9.56 million shares of the stock with an approximate value of $$9.53 million in LCTX stocks shares; and BLACKROCK INC., currently with $$8.45 million in LCTX stock with ownership which is approximately 4.488%.
